clinical topic updates by Caron A. Jacobson, MD, MMSc
Chimeric antigen receptor (CAR) T-cell therapy has been approved by the US Food and Drug Administration (FDA) for patients with relapsed/refractory...READ MORE
Bruton tyrosine kinase (BTK) inhibitor therapy has transformed the management of relapsed mantle cell lymphoma (MCL). The second-generation agents ...READ MORE
patient care perspectives by Michael C. Heinrich, MD
The risk of recurrence, growth, and spread of gastrointestinal stromal tumors (GIST) after surgery relates to key variables such as the size, locat......READ MORE
Treatment intensity in mantle cell lymphoma (MCL) has traditionally been guided by factors such as patient age and fitness vs frailty. While these ...READ MORE
Patients with mantle cell lymphoma (MCL) who are asymptomatic and present indolently may be observed for a period of time prior to treatment initia...READ MORE
